Mosedipimod
Tier C — Watch / tradeMosedipimod
Targets：TLR4
Indications (approved)：Atopic dermatitis, COVID-19, 发热性中性粒细胞减少症, Stomatitis, Neutropenia
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| EC-18 | - | 1-acetoxy-3-(palmitoyloxy)propan-2-yl (9Z,12Z)-octadeca-9,12-dienoate |
| EC-18-001 | 542-44-9 | 2,3-dihydroxypropyl palmitate |
| EC-18-002 | 69256-58-2 | 2-hydroxy-3-(trityloxy)propyl palmitate |
| EC-18-003 | 60-33-3 | (9Z,12Z)-octadeca-9,12-dienoic acid |
| EC-18-004 | 920271-16-5 | 1-(palmitoyloxy)-3-(trityloxy)propan-2-yl (9Z,12Z)-octadeca-9,12-dienoate |
Frequently asked questions
What are the approved indications of Mosedipimod?
Approved indications include: Atopic dermatitis, COVID-19, 发热性中性粒细胞减少症, Stomatitis, Neutropenia.
When does the Mosedipimod patent expire?
No public expiry year is available for Mosedipimod yet; this page updates once verified.
How many synthesis routes are recorded for Mosedipimod?
1 synthesis routes are recorded; the shortest is 3 steps with 63.5 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Mosedipimod intermediates?
All intermediates in Mosedipimod routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Mosedipimod intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09